295 related articles for article (PubMed ID: 25583989)
1. A hypertrophic cardiomyopathy-associated MYBPC3 mutation common in populations of South Asian descent causes contractile dysfunction.
Kuster DW; Govindan S; Springer TI; Martin JL; Finley NL; Sadayappan S
J Biol Chem; 2015 Feb; 290(9):5855-67. PubMed ID: 25583989
[TBL] [Abstract][Full Text] [Related]
2. Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy.
Kuster DWD; Lynch TL; Barefield DY; Sivaguru M; Kuffel G; Zilliox MJ; Lee KH; Craig R; Namakkal-Soorappan R; Sadayappan S
Cardiovasc Res; 2019 Dec; 115(14):1986-1997. PubMed ID: 31050699
[TBL] [Abstract][Full Text] [Related]
3. MYBPC3's alternate ending: consequences and therapeutic implications of a highly prevalent 25 bp deletion mutation.
Kuster DW; Sadayappan S
Pflugers Arch; 2014 Feb; 466(2):207-13. PubMed ID: 24327208
[TBL] [Abstract][Full Text] [Related]
4. The HCM-linked W792R mutation in cardiac myosin-binding protein C reduces C6 FnIII domain stability.
Smelter DF; de Lange WJ; Cai W; Ge Y; Ralphe JC
Am J Physiol Heart Circ Physiol; 2018 Jun; 314(6):H1179-H1191. PubMed ID: 29451820
[TBL] [Abstract][Full Text] [Related]
5. Variable cardiac myosin binding protein-C expression in the myofilaments due to MYBPC3 mutations in hypertrophic cardiomyopathy.
Parbhudayal RY; Garra AR; Götte MJW; Michels M; Pei J; Harakalova M; Asselbergs FW; van Rossum AC; van der Velden J; Kuster DWD
J Mol Cell Cardiol; 2018 Oct; 123():59-63. PubMed ID: 30170119
[TBL] [Abstract][Full Text] [Related]
6. The mechanics of the heart: zooming in on hypertrophic cardiomyopathy and cMyBP-C.
Suay-Corredera C; Alegre-Cebollada J
FEBS Lett; 2022 Mar; 596(6):703-746. PubMed ID: 35224729
[TBL] [Abstract][Full Text] [Related]
7. E258K HCM-causing mutation in cardiac MyBP-C reduces contractile force and accelerates twitch kinetics by disrupting the cMyBP-C and myosin S2 interaction.
De Lange WJ; Grimes AC; Hegge LF; Spring AM; Brost TM; Ralphe JC
J Gen Physiol; 2013 Sep; 142(3):241-55. PubMed ID: 23980194
[TBL] [Abstract][Full Text] [Related]
8. Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice.
Barefield D; Kumar M; Gorham J; Seidman JG; Seidman CE; de Tombe PP; Sadayappan S
J Mol Cell Cardiol; 2015 Feb; 79():234-43. PubMed ID: 25463273
[TBL] [Abstract][Full Text] [Related]
9. Localization of the binding site of the C-terminal domain of cardiac myosin-binding protein-C on the myosin rod.
Flashman E; Watkins H; Redwood C
Biochem J; 2007 Jan; 401(1):97-102. PubMed ID: 16918501
[TBL] [Abstract][Full Text] [Related]
10. COOH-terminal truncated cardiac myosin-binding protein C mutants resulting from familial hypertrophic cardiomyopathy mutations exhibit altered expression and/or incorporation in fetal rat cardiomyocytes.
Flavigny J; Souchet M; Sébillon P; Berrebi-Bertrand I; Hainque B; Mallet A; Bril A; Schwartz K; Carrier L
J Mol Biol; 1999 Nov; 294(2):443-56. PubMed ID: 10610770
[TBL] [Abstract][Full Text] [Related]
11. Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function.
van Dijk SJ; Paalberends ER; Najafi A; Michels M; Sadayappan S; Carrier L; Boontje NM; Kuster DW; van Slegtenhorst M; Dooijes D; dos Remedios C; ten Cate FJ; Stienen GJ; van der Velden J
Circ Heart Fail; 2012 Jan; 5(1):36-46. PubMed ID: 22178992
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue.
Wijnker PJ; Friedrich FW; Dutsch A; Reischmann S; Eder A; Mannhardt I; Mearini G; Eschenhagen T; van der Velden J; Carrier L
J Mol Cell Cardiol; 2016 Aug; 97():82-92. PubMed ID: 27108529
[TBL] [Abstract][Full Text] [Related]
13. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction.
van Dijk SJ; Dooijes D; dos Remedios C; Michels M; Lamers JM; Winegrad S; Schlossarek S; Carrier L; ten Cate FJ; Stienen GJ; van der Velden J
Circulation; 2009 Mar; 119(11):1473-83. PubMed ID: 19273718
[TBL] [Abstract][Full Text] [Related]
14. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.
Stöhr A; Friedrich FW; Flenner F; Geertz B; Eder A; Schaaf S; Hirt MN; Uebeler J; Schlossarek S; Carrier L; Hansen A; Eschenhagen T
J Mol Cell Cardiol; 2013 Oct; 63():189-98. PubMed ID: 23896226
[TBL] [Abstract][Full Text] [Related]
15.
Desai D; Song T; Singh RR; Baby A; McNamara J; Green L; Nabavizadeh P; Ericksen M; Bazrafshan S; Natesan S; Sadayappan S
bioRxiv; 2024 May; ():. PubMed ID: 38853909
[TBL] [Abstract][Full Text] [Related]
16. Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice.
Fraysse B; Weinberger F; Bardswell SC; Cuello F; Vignier N; Geertz B; Starbatty J; Krämer E; Coirault C; Eschenhagen T; Kentish JC; Avkiran M; Carrier L
J Mol Cell Cardiol; 2012 Jun; 52(6):1299-307. PubMed ID: 22465693
[TBL] [Abstract][Full Text] [Related]
17. Contractile dysfunction in a mouse model expressing a heterozygous MYBPC3 mutation associated with hypertrophic cardiomyopathy.
Barefield D; Kumar M; de Tombe PP; Sadayappan S
Am J Physiol Heart Circ Physiol; 2014 Mar; 306(6):H807-15. PubMed ID: 24464755
[TBL] [Abstract][Full Text] [Related]
18. Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.
Flenner F; Geertz B; Reischmann-Düsener S; Weinberger F; Eschenhagen T; Carrier L; Friedrich FW
J Physiol; 2017 Jun; 595(12):3987-3999. PubMed ID: 28090637
[TBL] [Abstract][Full Text] [Related]
19. Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes.
Monteiro da Rocha A; Guerrero-Serna G; Helms A; Luzod C; Mironov S; Russell M; Jalife J; Day SM; Smith GD; Herron TJ
J Mol Cell Cardiol; 2016 Oct; 99():197-206. PubMed ID: 27620334
[TBL] [Abstract][Full Text] [Related]
20. Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy.
Helms AS; Tang VT; O'Leary TS; Friedline S; Wauchope M; Arora A; Wasserman AH; Smith ED; Lee LM; Wen XW; Shavit JA; Liu AP; Previs MJ; Day SM
JCI Insight; 2020 Jan; 5(2):. PubMed ID: 31877118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]